On Topic Virtual Roundtable: Multidisciplinary Perspectives on the Changing Care of Relapsed/Refractory Multiple Myeloma
Release Date: August 24, 2021
Expiration Date: August 23, 2022
The target audience for this activity is for community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.
After participating in this activity, participants should be better able to:
- Discuss factors that impact the selection of therapy for patients at first relapse, including certain patient- and disease-related factors, as well as previous agents received
- Assess treatment strategies for patients with MM that are in their 2nd relapse and beyond, including the incorporation of recently approved agents and the potential for clinical trial enrollment exploring novel regimens
- Develop strategies to optimize patient related outcomes, including mitigating adverse events, improving quality of life, and recognizing the role of the patient voice in selecting therapeutic approaches
Topics of Discussion
- Setting the Stage for Success
- The Changing Therapeutic Landscape for Relapsed/Refractory Multiple Myeloma
- Practical Approaches to Patient-Centered Care & Key Takeaways
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Method of Participation
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must:
All faculty and planning committee members have no conflicts to disclose with the exception of the following:
Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Chief Medical Officer, International Myeloma Foundation
Consultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research Institute
Adjunct Professor, College of Health Solutions, Arizona State University
Caitlin Costello, MD
Associate Clinical Professor of Medicine
UC San Diego Health
UCSD/Sharp Healthcare Transplant Program
Blood & Marrow Transplant Services
Moores Cancer Center
La Jolla, CA
Sandra Kurtin, PhD, ANP-C, AOCN
Assistant Professor of Clinical Medicine
Assistant Professor of Nursing
The University of Arizona Cancer Center
Co-Leader, Multiple Myeloma San Diego Support Group
15-year Multiple Myeloma Survivor
Faculty and Planning Committee Disclosures
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.
Faculty and Patient Advocate
Joseph Mikhael, MD, MEd, FRCPC, FACP (Moderator)
Consulting Fees: Amgen Inc., Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Oncology, Karyopharm Therapeutics, Oncopeptides, Inc., Sanofi
Caitlin Costello, MD
Consultant/Research Funding: Bristol Myers Squibb Company, Janssen Oncology, Takeda
Sandra Kurtin, PhD, ANP-C, AOCN
Consultant: Amgen, Bristol Myers Squibb Company, GlaxoSmithKline, Sanofi, Incyte Corporation
No relevant financial relationships to disclose
The following planning committee members have nothing to disclose except for the following:
Sara Fagerlie, PhD, CHCP
Consultant: Adaptive Biotechnologies
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Chloe Dunnam; Kraig Steubing
This activity is supported by independent educational grants from AbbVie, Inc., Karyopharm Therapeutics, Sanofi, Oncopeptides Inc.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.